Alto Neuroscience, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
Alto Neuroscience, Inc. (ANRO) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $4.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-12
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $4.00K, a 76.47% decline year-over-year.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$9.00K, a 107.83% decline year-over-year.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $8.00K.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$17.00K.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $123.00K.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$22.00K.
- Alto Neuroscience, Inc. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$33.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.00K 10-Q · filed 2026-08-12 | -$5.00K 10-Q · filed 2026-08-12 | $3.00K derived: sum of 3 quarters · filed 2026-08-12 | -$14.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$9.00K 10-Q · filed 2026-08-12 | -$1.00K derived: sum of 2 quarters · filed 2026-08-12 | -$18.00K derived: sum of 3 quarters · filed 2026-08-12 | -$1.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$9.00K derived: sum of 2 quarters · filed 2026-03-16 | $8.00K derived: sum of 3 quarters · filed 2026-08-12 | $123.00K 10-K · filed 2026-03-16 |
| 2025-09-30 | -$17.00K 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $115.00K 10-Q · filed 2025-11-12 | $109.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $17.00K 10-Q · filed 2026-08-12 | $132.00K 10-Q · filed 2026-08-12 | $126.00K derived: sum of 3 quarters · filed 2026-08-12 | $120.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $115.00K 10-Q · filed 2026-08-12 | $109.00K derived: sum of 2 quarters · filed 2026-08-12 | $103.00K derived: sum of 3 quarters · filed 2026-08-12 | $98.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2024-12-31 | -$6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$12.00K derived: sum of 2 quarters · filed 2026-03-16 | -$17.00K derived: sum of 3 quarters · filed 2026-03-16 | -$22.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | -$6.00K 10-Q · filed 2025-11-12 | -$11.00K derived: sum of 2 quarters · filed 2025-11-12 | -$16.00K 10-Q · filed 2025-11-12 | -$9.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$5.00K 10-Q · filed 2025-11-12 | -$10.00K 10-Q · filed 2025-08-13 | -$3.00K derived: sum of 3 quarters · filed 2025-11-12 | -$13.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | -$5.00K 10-Q · filed 2025-11-12 | $2.00K derived: sum of 2 quarters · filed 2025-11-12 | -$8.00K derived: sum of 3 quarters · filed 2025-11-12 | -$19.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$3.00K derived: sum of 2 quarters · filed 2025-03-20 | -$14.00K derived: sum of 3 quarters · filed 2025-03-20 | -$33.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | -$10.00K 10-Q · filed 2024-11-12 | -$21.00K derived: sum of 2 quarters · filed 2024-11-12 | -$40.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$11.00K 10-Q · filed 2024-08-13 | -$30.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | -$19.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |